Eli Lilly's Challenges
Eli Lilly faces unexpected revenue drops for its GLP1 drugs, Zepbound and Mounjaro, attributed to supply issues rather than demand. Analysts suggest that compounded GLP1 alternatives may be impacting sales, as new market players leverage innovative marketing strategies. The conversation raises questions about the true reasons behind Lilly's struggles in a competitive landscape.In this clip
From this podcast
Prof G Markets
Meta’s AI Promise, Microsoft’s Disappointing Beat & Why Google Should Spin Youtube | Prof G Markets
Related Questions